Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/5/2026 | $1.00 | Buy | Ladenburg Thalmann |
| 7/18/2025 | $5.00 | Buy | Maxim Group |
8-K - Akari Therapeutics Plc (0001541157) (Filer)
424B5 - Akari Therapeutics Plc (0001541157) (Filer)
8-K - Akari Therapeutics Plc (0001541157) (Filer)
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala. In this segment, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, provides a corporate update highlighting the Company's progress in 2025, key scientific and operational milestones achieved, and how these advances position Akari for a potential transition to a clinical-stage oncology company in 2026. Utilizing its innovativ
In-person presentation on Tuesday, January 13th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones for 2026 TAMPA, Fla. and LONDON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics will present at the 2026 Biotech Showcase being held from January 12-14, 2026 in San Francisco, CA. Presentation details are as follows: Date/Time: Tuesday, January 13, 2026 at 9:30 AM PSTL
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today issued the following letter to shareholders from its President and Chief Executive Officer, Abizer Gaslightwala. Dear Fellow Shareholders, As 2025 concludes, I am pleased to reflect on a year of meaningful progress and significant achievements towards creating best-in-class ADCs to transform current cancer therapies. With each forward step and each new milestone, we are advancing our mission to bring our innovative and uniquely designed ADCs to cancer patie
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
Ladenburg Thalmann initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $1.00
Maxim Group initiated coverage of Akari Therapeutics with a rating of Buy and set a new price target of $5.00
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
4 - Akari Therapeutics Plc (0001541157) (Issuer)
BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointment of Dr. Sara Hurvitz. "The formation of our SAB marks an important step in advancing Akari's scientific and clinical strategy, and we are honored to welcome Dr. Sara Hurvitz as its inaugural member," commented Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "In addition to her wealth of knowledge around ADCs, Dr. Hurvitz brings exceptional clinical expertise in the management of can
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15. She succeeds Alan Holmer, who will remain on the Board. "We thank Alan for his over ten years of dedicated service as founding Chair of the Corbus Board," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "Rachelle is a seasoned biopharmaceutical executive, and we have greatly benefitted from her innovative and strategic thinking as a Board member. We look forward to following her vision and continued leadership as we
Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development
BOSTON and LONDON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. At a General Meeting held in relation to the merger at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London, shareholders approved the Company's issuance of shares in connection with the proposed merger, with approximately 99% of shares present at the General Meeting, in person or by proxy, voted in support. "I am thrilled to announce this
BOSTON and LONDON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the effectiveness of the Form S-4, originally filed with the SEC on September 13, 2024 related to the merger of Akari Therapeutics, Plc (the Company) and Peak Bio, Inc. The Form S-4 was declared effective by the SEC on October 11, 2024 allowing the Company to definitively schedule the General Meeting to be held in relation to the merger. The General Meeting will be held at 9:00 a.m. Eastern Time on Thursday, November 7, 2024 at the Company's offices in London. "I am so excited to be
Interim CEO employment contract consists solely of equity compensationSamir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders. Dr. Patel will be compen
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D/A - Akari Therapeutics Plc (0001541157) (Subject)
SC 13D - Akari Therapeutics Plc (0001541157) (Subject)